This IP solution aims to enhance the efficacy of Natural Killer (NK) cell therapy in cancer immunotherapy. By targeting the ADAM17 gene using CRISPR technology, it intends to maintain the expression of CD16 on NK cells, crucial for antibody-directed cell cytotoxicity (ADCC) against tumor cells. Cryopreserved ADAM17 knockout (KO) NK cells demonstrated significantly higher CD16 expression post-thaw, leading to enhanced ADCC against cancer cell lines when combined with antibodies. This advancement addresses a critical issue in cancer immunotherapy and ensures sustained antitumor activity of NK cells even after cryopreservation. It holds potential applications in various off-the-shelf adaptive NK cell products, catering to a wide range of cancer types and patient needs. Companies in cellular immunotherapy may find this IP valuable for developing next-generation NK cell therapies with improved efficacy and versatility. With further development and testing planned—including evaluation in in vivo models and expansion using different cytokines—the IP presents a promising avenue for advancing cancer treatment strategies.